2023-05-05T09:35:55-05:00 2022-06-30 650715836 ZOMMA GROUP LLP 355 ALHAMBRA CIRCLE SUITE 1100 CORAL GABLES FL 33134 990 2021-07-01 201048322 COPD FOUNDATION INC COPD 8667312673 3300 PONCE DE LEON BLVD MIAMI FL 33134 KALEO CURTIS CFO 8667312673 2023-05-01 1 KALEO CURTIS 999009999 MARGARITA G LISKER CPA P00957338 3054448288 2023-05-01 3 AAL1 IAL1 2021 2023-04-26 12:10:37Z RUTH TAL-SINGER 3300 PONCE DE LEON BLVD MIAMI FL 33134 10101706 0 X WWW.COPDFOUNDATION.ORG X 2004 FL SEE SCHEDULE O.THE COPD FOUNDATION IS A PATIENT-CENTERED ORGANIZATION COMMITTED TO PREVENTING COPD, BRONCHIECTASIS, AND NONTUBERCULOUS MYCOBACTERIAL (NTM) LUNG DISEASE, AND TO SEEKING CURES WHILE IMPROVING LIVES AND ADVOCATING FOR ALL AFFECTED. 13 13 41 287 0 0 8102975 7630964 100400 102525 293300 260858 476980 0 8973655 7994347 200596 40000 0 0 3140171 3274953 0 0 833073 5175950 5199038 8516717 8513991 456938 -519644 10791127 9619205 2814685 2819631 7976442 6799574 X THE COPD FOUNDATION WAS ESTABLISHED TO IMPROVE THE LIVES OF PEOPLE WITH COPD, BRONCHIECTASIS, AND NONTUBERCULOUS MYCOBACTERIAL (NTM) LUNG DISEASE THROUGH INITIATIVES THAT EXPAND SERVICES AND SPEED INNOVATIONS WHICH WILL MAKE TREATMENT MORE EFFECTIVE AND AFFORDABLE.WE DO THIS THROUGH SCIENTIFIC RESEARCH, EDUCATION, ADVOCACY, AND AWARENESS WITH THE GOAL OF DISEASE PREVENTION, SLOWED PROGRESSION, AND ULTIMATELY A CURE. 0 0 4946626 40000 1076447 RESEARCH & MEDICALTHE COPD360 UNIQUE RESEARCH AND THERAPEUTICS DEVELOPMENT PLATFORM INCLUDES MULTIPLE ELEMENTS SUCH AS TWO PATIENT REGISTRIES, COPD PATIENT POWERED RESEARCH NETWORK (COPD PPRN) AND THE BRONCHIECTASIS AND NTM RESEARCH REGISTRY (BRR), TWO INTERACTIVE MODERATED SOCIAL PLATFORMS ENGAGING OVER 60,000 INDIVIDUALS GLOBALLY, COPD360SOCIAL AND BRONCHANDNTM360SOCIAL, AND THE RECENTLY LAUNCHED DIGITAL AND THERAPEUTICS NETWORK, COPD360NET. COPD360NET SUPPORTS THE DEVELOPMENT AND ADOPTION OF NOVEL DIGITAL HEALTH TOOLS, MEDICAL DEVICES AND THERAPEUTICS THAT TREAT COPD, BRONCHIECTASIS, AND NONTUBERCULOUS MYCOBACTERIAL (NTM) LUNG DISEASE. IN ORDER TO ADVANCE THE DEVELOPMENT OF NEW MEDICINES, OR THE REPURPOSING OF EXISTING DRUGS, A NEW APPROACH IS NEEDED. IN ADDITION, COPD360NET IS FOCUSED ON IMPLEMENTATION SCIENCE FACILITATING DISCOVERY TO DELIVERY.COVID-19 RELATED RESEARCHAT THE ONSET OF THE COVID-19 PANDEMIC, WE FOCUSED ON LISTENING TO OUR COMMUNITY AND PROVIDING PEOPLE WITH ACCURATE, TIMELY, AND TRUSTED INFORMATION. WE LAUNCHED A SERIES OF GLOBAL SURVEYS TO CAPTURE THE EXPERIENCES OF HEALTH CARE PROVIDERS AND PEOPLE LIVING WITH COPD, BRONCHIECTASIS, ALPHA-1 ANTITRYPSIN DEFICIENCY, AND NTM LUNG INFECTIONS DURING THE COVID-19 PANDEMIC. AN IMPORTANT INSIGHT FROM THIS SURVEY SERIES WAS THE INCREASED IMPORTANCE AND RELIANCE ON TELEMEDICINE AND VIRTUAL PLATFORMS TO CONNECT WITH EACH OTHER, HEALTH CARE PROFESSIONALS, AND HEALTH AND WELLNESS PROGRAMS. BRONCHIECTASISANDNTM360 ADDRESSES THE UNMET NEEDS OF THE BRONCHIECTASIS AND NONTUBERCULOUS MYCOBACTERIA (NTM) COMMUNITIES. THE 360 FRAMEWORK OFFERS A GLOBAL ONLINE PLATFORM FOR COMMUNITY MEMBERS TO CONNECT AND INTERACT, EDUCATIONAL RESOURCES FOR PATIENTS, AND RESEARCH PROGRAMS MEANT TO ASSIST IN ACCELERATING THERAPEUTIC SOLUTIONS AND CURES FOR BOTH, BRONCHIECTASIS AND NTM. WE ARE FORTUNATE TO BE ABLE TO WORK COLLABORATIVELY AMONG ALL STAKEHOLDER GROUPS INCLUDING PATIENTS, CAREGIVERS, HEALTH CARE PROVIDERS, PHARMACEUTICAL COMPANIES, AND DEVICE MANUFACTURERS TO OFFER PROGRAMS CRITICAL TO OUR COMMON MISSION. 556959 PUBLIC & PROFESSIONAL EDUCATIONTHE COPD FOUNDATION ENSURES THAT EVIDENCE-BASED, CURRENT EDUCATION CONTINUES TO BE AVAILABLE TO ALL STAKEHOLDERS, INCLUDING PATIENTS, CAREGIVERS, AND HEALTH CARE PROVIDERS. WHILE COVID-19 WAS A CRITICAL FOCUS OF OUR FY22 EDUCATION, OUR COMMUNITY ALSO EXPRESSED THE NEED TO ADDRESS OTHER CRITICALLY IMPORTANT ISSUES, SUCH AS COPING WITH A DIAGNOSIS AND STRESS, NUTRITION, EXERCISE, DEVICE TECHNIQUE, AND MANY MORE. TO THAT END, WE BOTH UPDATED OUR EXISTING LIBRARY AND DEVELOPED NEW PRINT, VIDEO, ONLINE, AND PODCAST EDUCATIONAL CONTENT. WE ALSO BEGAN TRANSLATING THESE TO SPANISH TO IMPROVE THE ACCESSIBILITY OF OUR CONTENT.WE PARTICIPATED IN THE ANNUAL GOLD MEETING, AND THE NHLBI CONSTITUENCY GROUP, AND CREATED THE EXPERT CONSENSUS MANUSCRIPT ON NEBULIZER USE. OXYTALK, AND FACEBOOK/YOUTUBE EVENTS WERE WELL RECEIVED (DO YOU KNOW ABOUT NTM LUNG DISEASE). A NEW "PATIENT BUNDLE" INCLUDES MY COPD ACTION PLAN AND OTHER RESOURCES. 415755 COMMUNITYTHE COPD360 COMMUNITY ENGAGEMENT COMMITTEE (COPD360CENCO), A DIVERSE PATIENTS AND CAREGIVERS COMMITTEE, WAS CREATED IN SEPTEMBER 2020 TO PROVIDE THE VOICE OF PATIENTS AND CAREGIVERS TO ALL OF THE COPD FOUNDATION'S EFFORTS, AND TO SUPPORT ITS INTERACTIONS WITH OTHER HEALTH CARE AND ADVOCACY ORGANIZATIONS. THE STRUCTURE FOR THE COPD360CENCO SUPPORTS THE DEVELOPMENT OF COPD360NET, WHILE ENHANCING THE COPD FOUNDATION'S REGULAR PRACTICE OF ENGAGING INDIVIDUALS WITH COPD, THEIR CAREGIVERS, AND FAMILIES.OUR WORK WITH OPELOUSAS HEALTH OF LOUISIANA PROMOTES COPD AWARENESS AND SELF-MANAGEMENT. THIS TARGETS AN UNDERSERVED POPULATION AND CONTAINS PATIENT AND PROVIDER MATERIALS. 239774 4D. POLICY & ADVOCACYTHE COPD FOUNDATION COMMUNITY WORKS WITH LOCAL, STATE, AND FEDERAL POLICY MAKERS TO INCREASE RESEARCH FUNDING, IMPROVE CARE DELIVERY, PROTECT ACCESS TO TREATMENTS, AND CREATE POLICY THAT IMPROVES THE LIVES OF THOSE WITH COPD, BRONCHIECTASIS AND NONTUBERCULOUS MYCOBACTERIAL (NTM) LUNG DISEASE. THE COPD FOUNDATION IS FOCUSING ITS 2022 ADVOCACY AND PUBLIC POLICY ACTIVITIES ON THREE MAIN AREAS:1. ACCESS TO SAFE, EFFECTIVE AND AFFORDABLE OXYGEN THERAPY2. ACCESS TO EFFECTIVE, AFFORDABLE PULMONARY REHABILITATION (IN PERSON OR VIA TELEHEALTH)3. IMPROVEMENT IN THE REGULATORY PROCESS OF QUALIFYING DRUG DEVELOPMENT TOOLS TO SUPPORT THE DEVELOPMENT OF NEW TREATMENTS FOR CHRONIC LUNG CONDITIONSIN FY22, WE FOCUSED OUR ADVOCACY STRATEGY ON THREE KEY AREAS: IMPROVED ACCESS TO AND REIMBURSEMENT OF PULMONARY REHABILITATION, SAFE AND EFFICIENT DELIVERY OF OXYGEN THERAPY, AND IMPROVED ACCEPTANCE OF NEW DRUG DEVELOPMENT TOOLS. OUR VIRTUAL IMPACT 2022 ADVOCACY EVENT DREW MORE THAN 50 ADVOCATES FROM AROUND THE UNITED STATES TO PARTICIPATE IN WORKSHOPS AND CALLS WITH THEIR ELECTED REPRESENTATIVES. PUBLICATIONS IN 2022CASABURI R, HESS M, PORSZASZ J, CLARK W, DIESEM R, TAL-SINGER R, FERGUSON C. EVALUATION OF OVER-THE-COUNTER PORTABLE OXYGEN CONCENTRATORS UTILIZING A METABOLIC SIMULATOR. RESPIR CARE. 2022 NOV 18:RESPCARE.10495. DOI: 10.4187/RESPCARE.10495. EPUB AHEAD OF PRINT. PMID: 36400446.MARTINEZ S, SULLIVAN J, PASQUALE C, CLARK B, MALANGA E, DEERING S, LIU L, STEPNOWSKY CJ. EFFECT OF TWO INTERVENTIONAL STRATEGIES ON IMPROVING CONTINUOUS POSITIVE AIRWAY PRESSURE ADHERENCE IN EXISTING COPD AND OBSTRUCTIVE SLEEP APNEA PATIENTS: THE O2VERLAP STUDY. CHRONIC OBSTR PULM DIS. 2022 JUL 29;9(3):394-412. DOI: 10.15326/JCOPDF.2022.0293. PMID: 35797447; PMCID: PMC9448010.CASABURI R, MERRILL D, DOLMAGE T, GARCIA-AYMERICH J, FAGERAS M, GOLDSTEIN R, HARDING G, KLINE LEIDY N, MALTAIS F, O'DONNELL D, PORSZASZ J, PUENTE-MAESTU L, RENNARD S, SCIURBA F, SPRUIT MA, TAL-SINGER R, TETZLAFF K, VAN'T HUL A, YU R, HAMILTON A. ENDURANCE TIME DURING CONSTANT WORK RATE CYCLE ERGOMETRY IN COPD: DEVELOPMENT OF AN INTEGRATED DATABASE FROM INTERVENTIONAL STUDIES. CHRONIC OBSTR PULM DIS. 2022 OCT 26;9(4):520-537. DOI: 10.15326/JCOPDF.2022.0331. PMID: 36066494; PMCID: PMC9718584.TAL-SINGER R, WALSH L, DEUBY T, SHAUGHNESSY A, HOTH KF, GASCON V, HINTRINGER S, HASS N, WINDERS T, MORGAN L, THOMASHOW B, MANNINO DM. TOBACCO INDUSTRY OWNERSHIP OF PHARMACEUTICAL COMPANIES: AN INTERNATIONAL SURVEY OF PEOPLE WITH RESPIRATORY DISEASE. THORAX. 2022 AUG 15:THORAXJNL-2022-219142. DOI: 10.1136/THORAX-2022-219142. EPUB AHEAD OF PRINT. PMID: 35970539.MANNINO DM, TAL-SINGER R. LONG-TERM TRENDS OF COPD MORTALITY: GAPS AND OPPORTUNITIES. RESPIROLOGY. 2022 NOV;27(11):914-915. DOI: 10.1111/RESP.14334. EPUB 2022 AUG 2. PMID: 35916275.SULLIVAN J, PASQUALE C, CLARK B, MALANGA E, MARTINEZ S, MANNINO D, STEPNOWSKY C. OUTCOMES IMPORTANT TO PATIENTS DIAGNOSED WITH BOTH COPD AND SLEEP APNEA: FINDINGS FROM THE O2VERLAP STUDY FOCUS GROUPS. CHRONIC OBSTR PULM DIS. 2022 JAN 27;9(1):45-54. DOI: 10.15326/JCOPDF.2021.0268. PMID: 34915602; PMCID: PMC8893966. EKSTRM M, MANNINO D. RESEARCH RACE-SPECIFIC REFERENCE VALUES AND LUNG FUNCTION IMPAIRMENT, BREATHLESSNESS AND PROGNOSIS: ANALYSIS OF NHANES 2007-2012. RESPIR RES. 2022 OCT 1;23(1):271. DOI: 10.1186/S12931-022-02194-4. ERRATUM IN: RESPIR RES. 2023 FEB 3;24(1):41. PMID: 36182912; PMCID: PMC9526909. MOLL M, HOBBS BD, MENON A, GHOSH AJ, PUTMAN RK, HINO T, HATA A, SILVERMAN EK, QUACKENBUSH J, CASTALDI PJ, HERSH CP, MCGEACHIE MJ, SIN DD, TAL-SINGER R, NISHINO M, HATABU H, HUNNINGHAKE GM, CHO MH. BLOOD GENE EXPRESSION RISK PROFILES AND INTERSTITIAL LUNG ABNORMALITIES: COPDGENE AND ECLIPSE COHORT STUDIES. RESPIR RES. 2022 JUN 17;23(1):157. DOI: 10.1186/S12931-022-02077-8. PMID: 35715807; PMCID: PMC9204872.BHUTANI M, PRICE DB, WINDERS TA, WORTH H, GRUFFYDD-JONES K, TAL-SINGER R, CORREIA-DE-SOUSA J, DRANSFIELD MT, PECH R, STOLZ D, HURST JR. QUALITY STANDARD POSITION STATEMENTS FOR HEALTH SYSTEM POLICY CHANGES IN DIAGNOSIS AND MANAGEMENT OF COPD: A GLOBAL PERSPECTIVE. ADV THER. 2022 JUN;39(6):2302-2322. DOI: 10.1007/S12325-022-02137-X. EPUB 2022 APR 28. PMID: 35482251; PMCID: PMC9047462.CASABURI R, MERRILL DD, HARDING G, LEIDY NK, ROSSITER HB, TAL-SINGER R, HAMILTON A; CBQC CONSTANT WORK RATE EXERCISE WORKING GROUP. A CONCEPTUAL FRAMEWORK FOR USE OF INCREASED ENDURANCE TIME DURING CONSTANT WORK RATE CYCLE ERGOMETRY AS A PATIENT-FOCUSED MEANINGFUL OUTCOME IN COPD CLINICAL TRIALS. CHRONIC OBSTR PULM DIS. 2022 APR 29;9(2):252-265. DOI: 10.15326/JCOPDF.2021.0258. PMID: 35018752; PMCID: PMC9166337.MARTINEZ FJ, AGUSTI A, CELLI BR, HAN MK, ALLINSON JP, BHATT SP, CALVERLEY P, CHOTIRMALL SH, CHOWDHURY B, DARKEN P, DA SILVA CA, DONALDSON G, DORINSKY P, DRANSFIELD M, FANER R, HALPIN DM, JONES P, KRISHNAN JA, LOCANTORE N, MARTINEZ FD, MULLEROVA H, PRICE D, RABE KF, REISNER C, SINGH D, VESTBO J, VOGELMEIER CF, WISE RA, TAL-SINGER R, WEDZICHA JA. TREATMENT TRIALS IN YOUNG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PRE-CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS: TIME TO MOVE FORWARD. AM J RESPIR CRIT CARE MED. 2022 FEB 1;205(3):275-287. DOI: 10.1164/RCCM.202107-1663SO. PMID: 34672872; PMCID: PMC8886994. 239774 6159114 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 0 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 61 0 1 41 1 0 0 0 0 0 1 1 0 0 0 0 X 13 13 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 FL X X THE ORGANIZATION 8667312673 3300 PONCE DE LEON BLVD MIAMI FL 33134 JAMES D CRAPO MD BOARD CHAIR 10.00 X X 0 0 0 WAYNE E WITHERS JR VICE-CHAIR, TREASURER 2.00 X X 0 0 0 JEAN WRIGHT MD MBA DIRECTOR, SECRETARY 2.00 X X 0 0 0 BYRON M THOMASHOW MD CHIEF MEDICAL OFFICER 2.00 X X 0 0 0 RICHARD CASABURI PHD MD DIRECTOR 2.00 X 0 0 0 STEW COGAN ESQ DIRECTOR 2.00 X 0 0 0 LEONARD FROMER MD DIRECTOR 2.00 X 0 0 0 DONALD GRAY DIRECTOR 2.00 X 0 0 0 MEILAN K HAN MD MS DIRECTOR 2.00 X 0 0 0 GERARD M TURINO MD DIRECTOR 2.00 X 0 0 0 ROBERT WISE MD DIRECTOR 2.00 X 0 0 0 HERB YARDLEY DIRECTOR 2.00 X 0 0 0 VINCENT MALANGA CHIEF INFORMATION OFFICER 40.00 X 209557 0 16878 SASHA LAVIN CHIEF FINANCIAL OFFICER 40.00 X 161435 0 8910 KRISTEN WILLARD EVP, PUBLIC & PROFESSIONAL EDUCATION 40.00 X 109515 0 14817 RUTH TAL-SINGER PHD PRESIDENT & CEO 40.00 X 300000 0 0 ELISHA MALANGA CHIEF OF STAFF 40.00 X 154149 0 34416 934656 0 75021 5 0 1 0 UNIVERSITY OF NORTH CAROLINA 104 AIRPORT DRIVE STE 2200 CHAPEL HILL NC 27599 CLINICAL STUDY CONTRACTOR 339578 TALSI TRANSLATIONAL MEDICINE CONSULTING 723 HEMLOCK ROAD MEDIA PA 19063 CONTRACTOR 300000 SCHEDULINGCOM 401 N MICHIGAN AVE STE 640 CHICAGO IL 60611 DATA COORDINATING CENTER 270747 UNIVERSITY OF MICHIGAN 1000 VICTORS WAY STE 1A ANN ARBOR MI 48108 CLINICAL STUDY CONTRACTOR 262578 PERL PLLC 350 E SHORT STREET UNIT 411 LEXINGTON KY 40507 CONTRACTOR 171500 16 197827 21817 7411320 7630964 PUBLICATION INCOME 511120 102525 102525 102525 142019 142019 2103805 1984966 118839 118839 118839 122393 197827 122393 0 7994347 0 0 363383 X 40000 40000 2642019 1607717 691515 342787 430915 252456 120007 58452 202019 124156 49077 28786 107794 79762 28032 4044362 3450530 301106 292726 52803 42618 2135 8050 95271 78764 16095 412 30871 30871 47778 8244 199 39335 12239 11494 745 7783 7783 50726 4838 44797 1091 LICENSES AND FEES 452852 307760 116560 28532 DUES & SUBSCRIPTIONS 86691 27250 33078 26363 BAD DEBT 82476 27470 55006 PRINTING AND PUBLICATIO 77934 76208 1726 49458 19847 24798 4813 8513991 6159114 1521804 833073 2474540 1784276 401725 197804 1672165 1693965 596356 527014 45703 22761 20324 22942 5188565 5000792 437452 392412 10791127 9619205 548534 903127 2266151 1916504 2814685 2819631 X 2899789 1898654 5076653 4900920 7976442 6799574 10791127 9619205 -519644 -657224 0 X X 0 1 X 1 0 X 9064117 9371908 8749406 8102975 7630964 42919370 9064117 9371908 8749406 8102975 7630964 42919370 6086679 36832691 63186 132557 134722 104551 142019 577035 43496405 0.84680 0.79340 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 45703 22761 22942 22942 X 7733489 0 7733489 260858 260858 7994347 8513991 0 8513991 0 8513991 PART X, LINE 2: THE ORGANIZATION IS ORGANIZED AS A NOT-FOR-PROFIT ENTITY AND IS EXEMPT FROM INCOME TAXES UNDER SECTION 501(C) (3) OF THE INTERNAL REVENUE CODE. UNRELATED BUSINESS INCOME, OF WHICH THE ORGANIZATION HAD NONE FOR THE YEARS ENDED JUNE 30, 2022 AND 2021, WOULD BE SUBJECT TO FEDERAL INCOME TAXES. THE ORGANIZATION'S INFORMATION RETURNS FILED WITH THE INTERNAL REVENUE SERVICE HAVE NOT BEEN EXAMINED IN THE PAST. THE ORGANIZATION IS NOT AWARE OF ANY UNCERTAINTIES THAT COULD JEOPARDIZE ITS NOT-FOR-PROFIT STATUS. THEREFORE, NO PROVISION OR LIABILITY FOR INCOME TAXES IS DEEMED NECESSARY. THE ORGANIZATION FOLLOWS THE PROVISIONS OF UNCERTAIN TAX PROVISIONS ADDRESSED BY FAS ASC 740-10 ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. THE ORGANIZATION HAS NO UNCERTAIN TAX POSITIONS AT JUNE 30, 2022 AND 2021, FOR WHICH THE ULTIMATE DEDUCTIBILITY IS HIGHLY CERTAIN BUT FOR WHICH THERE ARE UNCERTAINTY ABOUT THE TIMING OF SUCH DEDUCTIBILITY. THE ORGANIZATION RECOGNIZES INTEREST ACCRUED RELATED TO UNRECOGNIZED TAX BENEFITS IN INTEREST EXPENSE AND PENALTIES IN OPERATING EXPENSE. THE ORGANIZATION HAS DETERMINED THAT NO AMOUNT REQUIRED TO BE ACCRUED FOR TAXES OR RELATED PENALTIES AND INTEREST FOR ANY TAX POSITION TAKEN THROUGH JUNE 30, 2022 AND 2021. PART XI, LINE 4B - OTHER ADJUSTMENTS: INTEREST INCOME 16,106. DIVIDENDS 125,913. REALIZED GAIN ON SALES 118,839. 0 0 0 0 0 0 0 0 0 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 40000 WIRE 0 0 0 0 0 0 0 PART III ACCOUNTING METHOD: FUNDRAISING EVENT 320220 197827 122393 122393 320220 197827 122393 122393 122393 0 X X 0 0 0 0 0 0 0 0 0 RUTH TAL-SINGER PHD PRESIDENT & CEO 300000 0 0 0 0 0 0 0 0 0 300000 0 0 0 VINCENT MALANGA CHIEF INFORMATION OFFICER 209557 0 0 0 0 0 0 0 16878 0 226435 0 0 0 ELISHA MALANGA CHIEF OF STAFF 154149 0 0 0 0 0 0 0 34416 0 188565 0 0 0 SASHA LAVIN CHIEF FINANCIAL OFFICER 161435 0 0 0 0 0 0 0 8910 0 170345 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B AFTER REVIEW BY THE CFO, THE DRAFT FORM 990 IS CIRCULATED TO MEMBERS OF MANAGEMENT FOR REVIEW AND COMMENT. THE FORM 990 IS THEN PROVIDED TO THE FOUNDATION'S BOARD OF DIRECTORS FOR REVIEW PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C AT EACH BOARD MEETING THE CONFLICT OF INTEREST POLICY IS READ BEFORE THE CONDUCT OF ANY OTHER ITEM. WRITTEN CONFLICT OF INTEREST STATEMENTS ARE OBTAINED FROM ALL OFFICERS, BOARD MEMBERS, COMMITTEE MEMBERS, STAFF AND CONTRACTED PERSONNEL ANNUALLY. FAILURE TO FILE THE STATEMENT WILL RESULT IN THE PERSON BEING REMOVED FROM SERVICE ON ANY COMMITTEE FORM 990, PART VI, SECTION B, LINE 15 SALARIES FOR COPD FOUNDATION MANAGEMENT ARE DETERMINED BY ANNUAL SURVEYS OF COMPARABLE NOT-FOR-PROFIT ORANIZATIONS. FORM 990, PART VI, SECTION C, LINE 19 THE WEBSITE WWW.COPDFOUNDATION.ORG INCLUDES THE POSTING OF FINANCIAL STATEMENTS, FORM 990, ANNUAL REPORT, CONFLICT OF INTEREST POLICY AND WHISTLEBLOWER POLICY. FORM 990, PART IX, LINE 11G CONTRACT SERVICES: PROGRAM SERVICE EXPENSES 3,450,530. MANAGEMENT AND GENERAL EXPENSES 301,106. FUNDRAISING EXPENSES 292,726. TOTAL EXPENSES 4,044,362. PART XII, LINE 2C EXPLANATION THERE WERE NO CHANGES FROM THE PRIOR YEAR.